Till BG et al. - In a trial to analyse outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive pts with mantle cell lymphoma (MCL), it was shown that ASCT in CR1/PR1 leads to improved survival outcomes for pts with MCL compared with ASCT with relapsed/refractory disease, and a HyperCVAD with or without rituximab (+/-R) induction regimen may be associated with improved PFS among pts transplanted in CR1/PR1 Methods
21 pts received induction chemotherapy with HyperCVAD (+/-R) followed by ASCT in first complete or partial remission (CR1/PR1), 15 received CHOP (+/-R) followed by ASCT in CR1/PR1 and 20 received ASCT following disease progression
Results
Estimates of overall and progression-free survival (PFS) at 3 years among pts transplanted in CR1/PR1 were 93% and 63% vs 46% and 36% for pts transplanted with relapsed/refractory disease, respectively
The hazard of mortality among pts transplanted with relapsed/refractory disease was 6.09 times that of pts transplanted in CR1/PR1
Pts in the CHOP (+/-R) group had a higher risk of failure for PFS vs pts in the HyperCVAD (+/-R) group, though the difference did not reach statistical significance
See all
